Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Gossamer Bio (GOSS) EBT (2022 - 2025)

Historic EBT for Gossamer Bio (GOSS) over the last 4 years, with Q3 2025 value amounting to -$48.2 million.

  • Gossamer Bio's EBT fell 5099.73% to -$48.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$161.2 million, marking a year-over-year decrease of 12652.47%. This contributed to the annual value of -$55.6 million for FY2024, which is 6906.02% up from last year.
  • As of Q3 2025, Gossamer Bio's EBT stood at -$48.2 million, which was down 5099.73% from -$38.3 million recorded in Q2 2025.
  • Over the past 5 years, Gossamer Bio's EBT peaked at $53.7 million during Q2 2024, and registered a low of -$59.0 million during Q3 2022.
  • For the 4-year period, Gossamer Bio's EBT averaged around -$39.8 million, with its median value being -$44.7 million (2024).
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 22628.72% in 2024, then tumbled by 17131.57% in 2025.
  • Quarter analysis of 4 years shows Gossamer Bio's EBT stood at -$57.2 million in 2022, then rose by 15.85% to -$48.1 million in 2023, then grew by 26.4% to -$35.4 million in 2024, then plummeted by 36.07% to -$48.2 million in 2025.
  • Its EBT stands at -$48.2 million for Q3 2025, versus -$38.3 million for Q2 2025 and -$39.3 million for Q1 2025.